SCHEMBL6830207

SCHEMBL6830207

N#CC(C(=O)c1ccccc1C(F)(F)F)c1nc(-c2c(F)cccc2F)cs1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KMT2A Q03164 2/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ESR2 Q92731 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MRE11 P49959 1/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
CTNNB1 P35222 2/20 0.33
WNT3A P56704 2/20 0.33
MPL P40238 2/20 0.33
ADAM17 P78536 1/20 0.33
CDK2 P24941 1/20 0.33
RORB Q92753 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8683579 0.80 HSD17B10 (0.39) MEN1NPC1RAB9AKMT2ATP53
SCHEMBL8332823 0.76 HSD17B10 (0.39) MEN1NPC1RAB9AKMT2ATP53
SCHEMBL6662351 0.72 MAPT (0.41) MEN1NPC1RAB9AKMT2ATP53
SCHEMBL6662355 0.72 MAPT (0.41) MEN1NPC1RAB9AKMT2ATP53
SCHEMBL6826754 0.70 LMNA (0.50) SMN1; SMN2LMNAGAACTNNB1WNT3A
SCHEMBL29392950 0.69 MAPT (0.34) MEN1NPC1RAB9AKMT2ATP53
SCHEMBL29359396 0.69 MEN1 (0.47) MEN1NPC1RAB9AKMT2ATP53
SCHEMBL13558725 0.65 RAPGEF3 (0.40) LMNAGAA
SCHEMBL24910228 0.64 MPL (0.42) MEN1KMT2AMAPTL3MBTL1GAA
SCHEMBL6829927 0.61 GAA (0.43) MEN1KMT2AHTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040059122-A1 Cyanothioacetamide derivative and process for producing the same NIPPON SODA CO., LTD. (JP) 2004-03-25 US disclosed
EP-1367049-A1 CYANOTHIOACETAMIDE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME NIPPON SODA CO., LTD. (JP) 2003-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059122-A1 Cyanothioacetamide derivative and process for producing the same NAT1, ACAA2, ACAT2 MEN1 2943/4885NPC1 1787/4885RAB9A 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.